On November 1, 2023 Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, reported its participation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, November 1-5, 2023, in San Diego, CA (Press release, Aster Insights, NOV 1, 2023, View Source [SID1234636685]). Three presentations will be shared at this year’s SITC (Free SITC Whitepaper) meeting based on multimodal evidence from Total Cancer Care, the world’s largest and longest running observational research study in oncology, which has accrued nearly 400,000 patients. The schedule of presentations and highlights include:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Tim Shaw, Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines (Abstract 151)
Date: Friday, November 3, 2023
Importance of understanding the clonal structure of primary vs metastatic tumors to predict neoantigens for effective neoantigen-based cancer vaccines
Xuefeng Wang, Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors (Abstract 185)
Date: Friday, November 3, 2023
Utilizing patterns of copy number alterations to inform cancer prognosis
Michael Radmacher, Demonstration of the utility of real-world progression-free survival (rwPFS) by application of an IFN-γ-related signature in a real-world cohort of patients with melanoma (Abstract 898)
Date: Saturday, November 4, 2023
Application of Aster Insights’ real-world progression-free survival algorithm to demonstrate the utility of real-world data for confirming previously reported prognostic associations
The abstracts were published this week in the Journal for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (JITC). Aster Insights partners with 18 leading cancer centers that comprise the Oncology Research Information Exchange Network (ORIEN). All three studies being presented at SITC (Free SITC Whitepaper) this year stem from research conducted within ORIEN Immuno-Oncology Research Interest Group and were co-developed by ORIEN and Aster Insights scientists.
"These presentations at SITC (Free SITC Whitepaper) are a testament to the longstanding partnerships between Aster Insights and ORIEN," said Anand Shah, MD, Aster Insights CEO. "Over the years, our collaborative research in immuno-oncology has identified new treatments, supported drug and biomarker discovery, and provided novel insights for cancer care delivery."